Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Analysts are cautious, having chopped their estimates for fourth-quarter earnings growth to 1.5% from the previous year - or ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Nvidia stock is higher Tuesday after President Trump revoked a 2023 executive order targeting AI developers. Here's what we ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Stock futures ticked lower on Thursday night after the Dow Jones Industrial Average and the S&P 500 ended a three-day losing streak. Futures tied to the 30-stock Dow fell 41 points, or 0.1%. S&P 500 ...

UBS Securities Japan Co., Ltd. announced a series of senior-level sales hires in its Global Markets Division Tokyo, January 6, 2025 — UBS Securities Japan Co., Ltd. today announced a series of ...

During a recent press conference, Trump stated that he would not rule out using military or economic force to acquire ...

On Monday, Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.62 which represents a decrease of $-1.64 or -1.90% from the prior close of $86.26. The stock opened at $84.42 and touched a ...